Home › Studies › PRJNA1104421
PRJNA1104421 SRP503927

Severe alcoholic hepatitis, Amiens, pre/post steroids

Serum Bile Acids profiles are altered without change of the Gut Microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis

54 fecal metagenome samples from 27 severe alcoholic hepatitis patients at Amiens University Hospital, France, collected before and after a 7-day corticosteroid therapy course (longitudinal design). machine-written summary

54 samples · 54 runs · FR · Adult · 2024 · 1.85 Gbp / sample

Sources
✓Sequence archive 518✓Abstract / description 76✓Full text 54○Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive518 sample values (collection date, country, health condition, intervention, intervention detail, latitude, location locality, longitude)
✓ Abstract / description76 sample values (health condition, health condition detail)
✓ Full text54 sample values (location site) · PMC11290774
○ Supplementary tablesfiles read; no table could be matched to the samples
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention · arms resolved

before · no interventionbefore · no interventi27 samplesdrugdrug27 samples
single arm: samples before and on the intervention

27 people have samples in more than one arm.

Non-antibiotic pharmaceutical given as the study intervention (metformin design single_arm_before_after · population liver_disease · 7-day corticosteroid (prednisolone) therapy in severe alcoholic hepatitis

“before (D0) and after (D7) a 7-day corticotherapy course” — bioproject.description (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 sampling locations · 1 country
Age
adult54
Condition
liver_disease54
Country
FR54
Body site
primary54
Collected 2017–2023
2017: 2 samples2018: 4 samples2019: 4 samples2020: 14 samples2021: 2 samples2022: 12 samples2023: 16 samples20172023
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 1 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 29 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 19 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 5 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 2.22 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal

27 of 27 people sampled more than once (54 samples; median 2, up to 2 per person) · follow-up median 7 d (max 7 d) · median interval between samples 7 d (time from collection dates). Schedule stated by the source: “stool samples at D0 (before) and D7 (after 7-day corticotherapy course)” (time origin: treatment_start); stated follow-up 7 d.

BB.013BB.013: day 0BB.013: day 7BB.020BB.020: day 0BB.020: day 7BB.024BB.024: day 0BB.024: day 7BB.026BB.026: day 0BB.026: day 7BB.027BB.027: day 0BB.027: day 7BB.030BB.030: day 0BB.030: day 7BB.031BB.031: day 0BB.031: day 7BB.033BB.033: day 0BB.033: day 7BB.040BB.040: day 0BB.040: day 7BB.046BB.046: day 0BB.046: day 7BB.048BB.048: day 0BB.048: day 7BB.050BB.050: day 0BB.050: day 7BB.053BB.053: day 0BB.053: day 7BB.054BB.054: day 0BB.054: day 7BB.055BB.055: day 0BB.055: day 7BB.056BB.056: day 0BB.056: day 7BB.118BB.118: day 0BB.118: day 7BB.121BB.121: day 0BB.121: day 7BB.122BB.122: day 0BB.122: day 7BB.123BB.123: day 0BB.123: day 7BB.126BB.126: day 0BB.126: day 7BB.127BB.127: day 0BB.127: day 7BB.134BB.134: day 0BB.134: day 7BB.138BB.138: day 0BB.138: day 7HAA.03HAA.03: day 0HAA.03: day 7HAA.11HAA.11: day 0HAA.11: day 7HAA.16HAA.16: day 0HAA.16: day 70 d2 d4 d5 d7 d

Each row is one person (27 shown); dots are samples at days since that person's first sample.

How longitudinal and relatedness information is derived

Community composition
Bacteroides 15.2%Phocaeicola 12.4%Prevotella 12.3%Bifidobacterium 4.8%Faecalibacterium 3.5%Roseburia 3.1%Veillonella 2.2%Alistipes 2.2%Escherichia 2.1%Streptococcus 2.0%Blautia_A 1.7%Parabacteroides 1.6%not assigned to a genus 5.8%other genera 31.0%

Genera, mean relative abundance over 51 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category54 100%
country54 100%54
health_condition54 100%3222
subject_id54 100%54
collection_date54 100%54
detailed_location54 100%
health_condition_detail54 100%54
intervention54 100%54
intervention_detail54 100%54
latitude54 100%54
location_locality54 100%54
location_site54 100%54
longitude54 100%54
timepoint_label54 100%54
Papers (1)
  • Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis. 2024 PMID 39078043 PMC11290774 own_data
Details
Archive description

Severe Alcoholic Hepatitis (sAH) is an acute form of liver injury caused by chronic and heavy alcohol drinking. A one-month corticosteroids course is the only sAH reference treatment, and its interactions with the Gut Microbiota (GM), which is a key contributor to liver injury, remain unknown. To evaluate the evolution of the GM in sAH patients, we retrospectively investigated the composition of the GM of 27 sAH patients at the Amiens University Hospital before (D0) and after (D7) a 7-day corticotherapy course using fecal metagenomics sequencing. We also quantified fecal Short Chain Fatty Acids (SCFA) and fecal and serum Bile Acids (BA), as well as serum Lipopolysaccharide-Binding Protein (LBP). Overall, the community and taxonomical analyses did not reveal any GM evolution between D0 and D7, nor did the SCFA profiles analysis. However, in serum but not fecal samples, the ratio of glyco-conjugated to tauro-conjugated BA was significantly reduced at D7, independently of the response to treatment, while two BA were enriched in non-responder patients. LBP concentration significantly diminished between D0 and D7, which may indicate an improvement of the gut barrier. The stability of the GM of sAH is interesting in the perspective of new treatments based on GM modulation.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.70. Assay shotgun_dna.

  • host run.scientific_name · “human gut metagenome”
  • body site study.title · “change of the Gut Microbiota composition”
  • body site study.description · “fecal metagenomics sequencing”
  • life stage study.description · “Amiens University Hospital before”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN41077593collection_date2019-08-16R10.90biosample.attribute:collection_date2019-08-16
SAMN41077593countryFRR10.90sample.attr.geo_loc_nameFrance: Amiens
SAMN41077597health_conditionliver_diseaseR10.70biosample_attrPR_D0
SAMN41077593health_conditionliver_diseaseR40.50study.description27 sAH patients at the Amiens University Hospital
SAMN41077593health_condition_detailSevere Alcoholic HepatitisR40.50study.description27 sAH patients at the Amiens University Hospital
SAMN41077593interventionno_interventionR10.80biosample.attribute:GroupGroup: PNR_D0
SAMN41077593intervention_detailnon-responder, baseline before 7-day prednisoloneR10.80biosample.attribute:GroupGroup: PNR_D0
SAMN41077593latitude49.5200R10.90biosample.attribute:lat_lon49.52 N 2.15 E
SAMN41077593location_localityAmiensR10.85biosample.attribute:geo_loc_nameFrance: Amiens
SAMN41077593location_siteAmiens University HospitalR30.70paper.fulltext.abstract27 sAH patients at the Amiens University Hospital
SAMN41077593longitude2.1500R10.90biosample.attribute:lat_lon49.52 N 2.15 E
SAMN41077593subject_idBB.013R10.85sample.attr.individualBB.013
SAMN41077593timepoint_labelD0R10.85sample.attr.timeD0
Sequencing

54 runs over 54 samples · mean 2.94 Gbp per run (median 1.85 Gbp, total 158.73 Gbp; 54 runs with a base count) · layout PAIRED 54 · platform ILLUMINA 54 · models NextSeq 550 (54) · 93% of runs with a Sandpiper profile · first public 2024-07-23

Authors (11)

Esparteiro D first · Fouquet G · Courtois A · Jedraszak G · Marticho L · Gourdel M · Billon-Crossouard S · Croyal M · Naassila M · Nguyen-Khac E · Marcq I last

Downloads

PRJNA1104421.csv.gz (2.9 KB) · parquet (73.5 KB) — all 54 samples, every field with route and confidence · PRJNA1104421_determinations.csv.gz (5.3 KB) — 648 evidence rows

Samples (54 · every field this project has values for · hover a cell for its source)
Loading the sample table…